Skip to main content
. 2023 Jan 20;11(1):e005007. doi: 10.1136/jitc-2022-005007

Figure 1.

Figure 1

Individual serum concentrations of V937 on day 1, cycle 1, in cohort 3 and median serum concentrations of V937 antibodies over time in cohort 3. Part A (V937 monotherapy) is shown in panels A and B; part B (V937+pembrolizumab) is shown in panels C and D.